GlassScriptPhysician profile
Jai Eun Min
NPI 1508123019
$11,410.13
in general payments reported to CMS, 2019-2025
34 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $914 · 2021: $1,341 · 2022: $1,609 · 2023: $2,017 · 2024: $2,069 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,268 · Education: $58.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,267.55 |
| Education | $58.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,876.51 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,923.39 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $970.48 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $927.64 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $508.51 | 2019-2024 | Dificid |
| Pfizer INC. | $412.78 | 2019-2025 | |
| Daiichi Sankyo INC. | $381.17 | 2020-2025 | Injectafer |
| Genzyme Corporation | $362.93 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $346.66 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $295.44 | 2019-2025 | Epclusa, Livdelzi |
| Ardelyx, INC. | $231.42 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $174.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $166.25 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $165.54 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $155.21 | 2022-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $153.76 | 2024-2025 | Voquezna |
| Celltrion, INC. | $150.00 | 2025 | |
| Celltrion USA INC. | $140.78 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $133.68 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Intercept Pharmaceuticals, INC. | $116.46 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $115.37 | 2023-2025 | Zenpep |
| Celgene Corporation | $114.09 | 2022-2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $111.97 | 2023 | Utaswako Afp-L3 |
| Janssen Scientific Affairs, LLC | $105.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2023 | Zeposia |
| Qol Medical, LLC | $66.11 | 2023-2024 | Sucraid, Sucraid |
| Medtronic, INC. | $54.48 | 2023-2024 | Interstim, Signia |
| Ipsen Biopharmaceuticals, INC | $32.27 | 2025 | Iqirvo |
| Organon LLC | $26.90 | 2025 | Hadlima, Renflexis |
| Shire North American Group INC | $22.66 | 2019 | |
| Ethicon US, LLC | $20.44 | 2022 | |
| Fresenius Kabi USA, LLC | $18.63 | 2023 | Idacio |
| Braintree Laboratories, INC. | $15.73 | 2022 | |
| Allergan, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Eun Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.